Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Chemotherapy in Advanced Gastric or GEJ Adenocarcinoma
NCT03777657Phase 3Completed
- Sponsor
- BeiGene
- Start
- Dec 2018
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Tislelizumab + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoints: Overall Survival in PD-L1 Positive Participants and Overall Survival in the Intent-to-Treat (ITT) Analysis Set. Started Dec 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03777657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777657.